Mode
Text Size
Log in / Sign up

Sacubitril/valsartan shows greater LVMI regression than some antihypertensives in hypertension with remodelingNew Drug Shrinks Heart Muscle Better Than Old Options

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider tentative evidence for sacubitril/valsartan in LVMI regression in hypertension with remodeling.

This network meta-analysis, based on a systematic review, included 851 patients with essential hypertension and cardiovascular remodeling. It compared sacubitril/valsartan to active antihypertensive comparators (amlodipine, valsartan, enalapril, olmesartan) for effects on left ventricular mass index (LVMI) regression, with secondary outcomes including systolic and diastolic blood pressure and left ventricular ejection fraction (LVEF). The study setting and follow-up duration were not reported.

Main results showed sacubitril/valsartan achieved greater LVMI regression versus amlodipine (mean difference = -22.54 g/m2, 95% CI: -40.23, -4.86) and valsartan (mean difference = -11.34 g/m2, 95% CI: -21.45, -1.23). Comparisons to enalapril and olmesartan indicated numerically greater regression but were not statistically significant. For LVEF, there was no significant impact (P > 0.05). Absolute numbers for these outcomes were not reported.

Safety and tolerability data, including adverse events and discontinuations, were not reported. Key limitations include substantial heterogeneity in imaging assessment modalities, evidence of network incoherence, and low-to-very-low certainty of the main comparisons. Funding and conflicts of interest were not reported.

Practice relevance is restrained due to the tentative nature of the evidence; results should be regarded as tentative rather than definitive. Clinicians should consider these findings preliminary, awaiting higher-certainty data from more robust studies.

Imagine your heart is a muscle that has been overworked and swollen for years. For many people with high blood pressure, this muscle gets too thick, making it harder to pump blood. This condition is called left ventricular hypertrophy, or LVH.

Doctors have long searched for the best way to shrink this thickened muscle. A new analysis suggests one specific medicine might be the winner.

High blood pressure affects millions of people worldwide. Over time, the constant pressure forces the heart to work harder. Eventually, the heart muscle thickens, like a bicep growing from lifting heavy weights.

This thickening is dangerous. It can lead to heart failure, irregular heartbeats, and even heart attacks. The problem is that current treatments often focus only on lowering blood pressure numbers. They do not always fix the thickened muscle itself.

Patients need more than just lower numbers on a monitor. They need their heart structure to heal. Finding a drug that actually reverses this damage is a huge goal for heart health.

The Surprising Shift

For decades, doctors relied on standard blood pressure pills. Common choices include calcium channel blockers like amlodipine and older ACE inhibitors like enalapril. These drugs are safe and effective at controlling pressure.

However, they were not always great at shrinking the heart muscle. Some studies showed mixed results. Patients would take these pills for years, yet their heart remained thick.

But here is the twist. A new study compares a newer combination drug called sacubitril/valsartan against these older standards. The results show a clear difference in how well they reverse heart thickening.

What Scientists Didn't Expect

To understand the difference, think of your heart muscle like a door that has swollen shut. You need a key to open it.

Older drugs act like a gentle push. They help relax the door, but they might not open it fully. The new drug acts like a master key. It targets two pathways at once to force the door open wider.

This drug combines two actions. It blocks a hormone that makes the heart grow thick. At the same time, it boosts a natural protein that helps the heart relax and shrink. This dual action is what makes it special.

The Study Snapshot

Researchers looked at data from 11 different clinical trials. These trials involved 851 patients with high blood pressure and thickened hearts.

They compared the new drug against common alternatives like amlodipine, valsartan, enalapril, and olmesartan. The main goal was to measure how much the heart muscle index changed.

The study used advanced math to compare all these drugs at once. This method, called a network meta-analysis, gives a clearer picture than looking at single studies.

The results were promising for the new drug. Patients taking sacubitril/valsartan saw their heart muscle shrink significantly more than those on other drugs.

Specifically, the new drug reduced heart mass by about 22.5 grams per square meter compared to amlodipine. That is a massive difference in heart tissue.

It also outperformed valsartan alone. The reduction was about 11.3 grams per square meter better. Even though the numbers for other drugs looked similar, the new drug consistently showed the biggest drop in heart thickness.

This doesn't mean this treatment is available yet.

It is important to be honest about the timeline. These findings come from research data. They show what works in controlled trials, but they do not mean every doctor can prescribe it today.

The study also found that the new drug lowered blood pressure just as well as the others. This is good news. It means you get the structural fix without losing the benefit of lower pressure.

This research offers hope for millions of patients. It suggests that the future of heart treatment might involve fixing the heart's shape, not just its pressure.

However, scientists must be careful. The study noted some uncertainty in the data. Different hospitals measure heart thickness in different ways, which can confuse the results.

More research is needed to confirm these findings. Doctors will need to run larger trials to be sure. Until then, this information helps guide future medicine.

For now, the message is clear. If you have high blood pressure and a thickened heart, ask your doctor about the latest options. Science is moving fast to give you a stronger, healthier heart.

Study Details

Study typeMeta analysis
EvidenceLevel 1
PublishedApr 2026
View Original Abstract ↓
ObjectiveTo systematically evaluate the relative efficacy and impact on cardiac function of sacubitril/valsartan (Sac/Val) vs. active antihypertensive comparators represented in the eligible evidence base for reversing left ventricular hypertrophy (LVH) in patients with hypertension using network meta-analysis.MethodsPubMed, Embase, The Cochrane Library, CNKI, Wanfang Data, and SinoMed databases were searched from inception to December 2025 for randomized controlled trials (RCTs) evaluating sacubitril/valsartan vs. active antihypertensive comparators in patients with essential hypertension and cardiovascular remodeling. The primary outcome was the change in left ventricular mass index (LVMI). Network meta-analysis was performed using STATA 18.0 software based on the frequentist framework. Given the clinical heterogeneity in imaging assessment modalities, a random-effects model was employed to calculate the weighted mean difference (MD) and 95% confidence intervals (CI). The surface under the cumulative ranking curve (SUCRA) was used as a supportive ranking metric, whereas comparative interpretation primarily relied on effect estimates and their confidence intervals.ResultsEleven RCTs involving 851 patients were included. The network meta-analysis showed that Sac/Val achieved greater LVMI regression than Amlodipine (MD = −22.54 g/m2, 95% CI: −40.23, −4.86) and Valsartan (MD = −11.34 g/m2, 95% CI: −21.45, −1.23) in reversing LVMI. Compared with Enalapril and Olmesartan, Sac/Val also showed numerically greater LVMI regression, but these differences were not statistically significant. Sac/Val had the highest SUCRA value (96.4%); however, rankings were interpreted descriptively only, while comparative interpretation was primarily based on effect sizes and confidence intervals. Secondary outcome analysis indicated that while Sac/Val effectively reduced systolic and diastolic blood pressure, it had no significant impact on left ventricular ejection fraction (LVEF) (P > 0.05).ConclusionIn hypertensive patients with cardiovascular remodeling, sacubitril/valsartan was associated with greater LVMI regression than amlodipine and valsartan within the current network, whereas comparisons with enalapril and olmesartan remained inconclusive. Given the substantial heterogeneity, evidence of network incoherence, and low-to-very-low certainty of the main comparisons, these results should be regarded as tentative rather than definitive.Systematic Review RegistrationPROSPERO CRD420261281426.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.